Fostamatinib/R788

 主页 / 产品目录 / API / Fostamatinib/R788
Fostamatinib/R788

Fostamatinib/R788

编号ABP000970 化学名称Fostamatinib/R788 CAS901119-35-5 分子式C23H26FN6O9P 分子量580.4595 纯度 >98%

化学名称 : Fostamatinib/R788

CAS : 901119-35-5

英文名称: Fostamatinib/R788

英文同义词: 2H-Pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-

溶解度:Unknown

储存条件:at -20℃ 2 years

生物活性

Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. [1] The IC50 for peramivir is markedly lower than that for either zanamivir or oseltamivir. Peramivir increases survival in preclinical influenza models, including mouse and ferret models of highly pathogenic avian influenza H5N1. One day of treatment with peramivir is active, and multiple days of treatment rescues most or all mice with H5N1. Similar data have been obtained in ongoing murine experiments with seasonal influenza A (H1N1)/H274Y. After parenteral administration, peramivir reaches very high plasma concentrations. Peramivir is not metabolized, and is cleared by the means of renal filtration. It has a long half-life, especially in comparison with other neuraminidase inhibitors. Due to the failure of the metabolism of the antivirus compound peramivir, as well as its wide distribution and the excretion in the unchanged form in urine, dosing regimens can be adapted easily for patients with renal impairment and for pediatric populations. [2] Peramivir is originally developed by BioCryst Pharmaceuticals. And peramivir is designed to aim to an antiviral agent. Peramivir has been performed phase III clinical trials for the treatment of influenza

参考文献

[1] http://en.wikipedia.org/wiki/Peramivir

[2] Memoli MJ et al. Clin Infect Dis. 2010 May 1;50(9):1252-5.

询价